Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

COMy 2026 | The challenges of identifying and treating high-risk multiple myeloma

Meral Beksaç, MD, Istinye University Ankara Liv Hospital, Ankara, Turkey, discusses the challenges of identifying and treating high-risk multiple myeloma, including patients who may become refractory early despite initially appearing standard risk. She highlights the importance of recognizing these patients early to guide treatment strategies aimed at achieving deeper and more durable responses. This interview took place at the 12th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

So high-risk in myeloma is certainly an important topic because while the majority of myeloma patients are responding to treatment easily and having a fantastic outcome with the most recent quadruplets, there is still a subset of patients around a range of 15 to 20%, those patients have a high-risk future. Some of them are recognized at diagnosis, which is reflected by, for instance, by FISH...

So high-risk in myeloma is certainly an important topic because while the majority of myeloma patients are responding to treatment easily and having a fantastic outcome with the most recent quadruplets, there is still a subset of patients around a range of 15 to 20%, those patients have a high-risk future. Some of them are recognized at diagnosis, which is reflected by, for instance, by FISH. And in some reference centers with the gene expression profiling, that is also possible to demonstrate that. But despite all these genetic investigations, there are some subgroup of patients who, although they look like standard, they either may be refractory to the best regimen or may become refractory soon after the first induction or after the transplant. So this is a heterogeneous group of patients. They are all under the title of high risk. And how to approach this type of patients is a topic of interest and we are trying to recognize such cases ahead of time to allow them the best regimen not maybe in the first run but in the second run so that they can achieve deep and durable response.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.